Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
I-Mab
Biotech
I-Mab lays off 27% of workforce after CLDN18.2 bispecific pivot
Weeks after shifting its focus, the biotech said it has reduced its workforce by around 27% in conjunction with the pipeline reprioritization.
Nick Paul Taylor
Jan 29, 2025 7:56am
I-Mab pauses Sanofi-partnered prospect to focus on CLDN18.2
Jan 6, 2025 8:34am
Chutes & Ladders—Gilead's Merdad Parsey goes, Cassava loses CEO
Jul 19, 2024 8:00am
Lonza lands new CEO—Chutes & Ladders
Apr 5, 2024 8:30am
I-Mab sheds China footprint to transform into US-based biotech
Feb 7, 2024 8:50am
AbbVie axes I-Mab pact to exit fast-thinning race for CD47 space
Sep 25, 2023 7:30am
